

Covis Pharma Launches in Canada

Covis Pharma is proud to announce it has begun Canadian operations and has acquired from AstraZeneca the rights to ^{Pr}Alvesco[®] and ^{Pr}Omnaris[®] in Canada. Covis Pharma is a global specialty pharmaceutical company focused on the needs of patients with life-threatening and chronic illnesses.

We look forward to helping you meet the needs of your patients and want to assure you that continuity of supply for our medications is a high priority for Covis Pharma.



Alvesco[®] (ciclesonide) inhalation aerosol is indicated for prophylactic management of steroid-responsive bronchial asthma in adults, adolescents and children 6 years of age and older.



Omnaris[®] (ciclesonide) nasal spray is indicated for the treatment of seasonal allergic rhinitis, including hayfever, and perennial allergic rhinitis in adults and adolescents 12 years of age and older.

For important information on conditions of clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions and dosing for Alvesco[®] or Omnaris[®], please consult the respective Product Monographs, available by calling AstraZeneca Canada at 1-800-668-6000.



Alvesco[®] and Omnaris[®] are registered trademarks Covis Pharma BV, used under licence.